© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
LivaNova PLC (LIVN) stock remained unchanged at $78.18 a share on NASDAQ. The stock opened at $79.22, fluctuating between $77.11 to $79.27 during the session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | 79.22 | 79.27 | 77.15 | 78.18 | 552.41K |
| Sep 10, 2026 | 78.11 | 78.88 | 77.37 | 78.18 | 425.89K |
| Sep 09, 2026 | 80.22 | 80.37 | 78.11 | 78.93 | 674.36K |
| Sep 08, 2026 | 81.44 | 81.83 | 80.16 | 80.70 | 472.48K |
| Sep 04, 2026 | 80.67 | 82.22 | 80.39 | 81.92 | 334.17K |
| Sep 03, 2026 | 83.50 | 83.52 | 80.81 | 81.20 | 694.08K |
| Sep 02, 2026 | 80.16 | 83.32 | 80.16 | 82.40 | 769.44K |
| Sep 01, 2026 | 79.57 | 80.63 | 78.49 | 80.16 | 585.41K |
| Aug 31, 2026 | 79.86 | 80.15 | 77.28 | 79.81 | 593.72K |
| Aug 28, 2026 | 80.10 | 80.77 | 79.43 | 80.32 | 465.95K |
| Aug 27, 2026 | 79.34 | 80.27 | 78.96 | 80.03 | 611.27K |
| Aug 26, 2026 | 79.83 | 80.03 | 77.63 | 79.97 | 733.43K |
| Aug 25, 2026 | 78.73 | 79.59 | 77.90 | 79.41 | 562.92K |
| Aug 24, 2026 | 78.65 | 80.00 | 78.00 | 78.26 | 823.21K |
| Aug 21, 2026 | 78.80 | 79.56 | 77.94 | 78.74 | 440.21K |
| Aug 20, 2026 | 80.00 | 80.81 | 77.90 | 78.21 | 418.81K |
| Aug 19, 2026 | 80.82 | 81.66 | 80.41 | 80.84 | 496.65K |
| Aug 18, 2026 | 81.69 | 81.69 | 79.09 | 79.86 | 619.12K |
| Aug 17, 2026 | 81.38 | 81.91 | 80.82 | 81.48 | 445.06K |
| Aug 14, 2026 | 81.59 | 82.34 | 79.98 | 82.22 | 559.43K |
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
| Employees | 3300 |
| Beta | 0.87 |
| Sales or Revenue | $1.15B |
| 5Y Sales Change% | -0.062% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |